Brief: Appili Therapeutics Inc Expects To Report Early Data From Preseco Study In First Half Of 2021
02/12/2020 12:55
Dec 2 (Reuters) - Appili Therapeutics Inc APLI.TO :
* FIRST PATIENT DOSED IN APPILI THERAPEUTICS’ PHASE 3
CLINICAL
TRIAL OF AVIGAN® TABLETS (FAVIPIRAVIR) FOR THE TREATMENT OF
COVID-19 IN THE UNITED STATES
* APPILI THERAPEUTICS INC - EXPECTS TO REPORT EARLY DATA
FROM
PRESECO STUDY IN FIRST HALF OF 2021
Source text for Eikon: ID:nBw95ftLpa
Further company coverage: APLI.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez